The Chemopreventive Agent Development Research Group (CADRG) promotes and supports research on cancer preventive agent development, from preclinical studies to phase I clinical trials. The group’s projects aim to intercept the carcinogenic process by identifying and developing preventative agents with the potential to block, reverse, or delay the early stages of cancer. In addition, the group supports research on clinically translatable biomarkers that can be used to monitor tumor initiation and progression or assess efficacy of preventive interventions.
Read more About the Chemopreventive Agent Development Research Group.
News and Events
Immune Interception Approaches for Individuals at Risk for Pancreatic Cancer
Date Posted: December 13, 2023
Research Highlights: Repurposing Common Medications to Prevent Cancer
Date Posted: September 11, 2023
Chief, Chemopreventive Agent Development Research Group Position Available
Date Posted: August 21, 2023
Opportunities for Cancer Immune Health, Prevention, and Interception
Date Reviewed: September 13, 2023
Therapeutic and Preventative Cancer Vaccines: The Last 30 Years
Date Posted: May 8, 2023